TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights strong financial performance with significant growth in revenue and net income. The company's strategic initiatives, like the development of subcutaneous BRIUMVI and market expansion efforts, are promising. The Q&A section reveals optimism about future growth, despite some uncertainties in competitive dynamics and lack of specific guidance for 2026. The raised revenue guidance and strong market share growth for BRIUMVI further support a positive outlook. Overall, these factors suggest a likely positive stock price movement in the short term.
Key Financial Performance
Total Revenue $161.7 million, an increase of 93% compared to Q3 '24 and 15% over Q2 '25. The increase was driven by strong commercial performance, particularly from BRIUMVI sales.
Product Revenue $159.3 million, primarily driven by $152.9 million in U.S. BRIUMVI net sales.
U.S. BRIUMVI Net Sales $152.9 million, reflecting strong sequential and year-over-year growth. The growth was attributed to sustained physician engagement, increasing patient awareness, and positive real-world experiences.
Operating Expenses (R&D and SG&A) $86.6 million in Q3, up from $71 million in Q2 '25. The increase was due to continued investment in R&D for subcutaneous BRIUMVI and higher SG&A spend to support the commercial expansion of BRIUMVI.
Cash, Cash Equivalents, and Investment Securities $178 million as of the end of Q3 '25, reflecting a strong capital position after completing a $78 million share repurchase program.
GAAP Net Income $390.9 million or $2.43 per diluted share for Q3 '25, compared to $3.9 million or $0.02 per diluted share in Q3 '24. This includes a nonrecurring income tax benefit of approximately $365 million due to the release of a deferred tax asset valuation allowance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
BRIUMVI for relapsing MS: Continues to outperform expectations with U.S. net sales of $153 million in Q3 2025. The product has shown strong sequential and year-over-year growth, exceeding internal and market expectations. It is supported by favorable dynamics such as strong demand, physician engagement, and increasing patient awareness.
ENHANCE pivotal study: Aims to consolidate BRIUMVI's day 1 and day 15 doses into a single day 1 infusion. Enrollment is complete, and data is expected by mid-2026, with a potential launch in 2027.
Phase III subcutaneous ublituximab study: Testing self-administration options with two dosing schedules. Enrollment is progressing well, with data expected in late 2026 or early 2027 and potential approval in 2028.
Azer-cel CAR T therapy: In early development for progressive MS, with potential to be life-changing for patients.
Market expansion for BRIUMVI: The anti-CD20 class now represents nearly $10 billion in annual U.S. MS sales, with significant opportunity remaining as approximately half of patients are still on other therapies. BRIUMVI is positioned to become a multibillion-dollar brand in RMS.
Subcutaneous ublituximab: Expected to nearly double the total addressable market for BRIUMVI, providing a unique competitive advantage by offering both IV and self-administered CD20 options.
Financial performance: Total revenue reached $161.7 million in Q3 2025, a 93% increase compared to Q3 2024. Operating expenses are on track with full-year guidance, and the company reported its sixth consecutive quarter of profitability.
Share repurchase program: Completed a $100 million share repurchase program, buying back 3.5 million shares at an average price of $28.50. A new $100 million program has been authorized.
Strategic focus on innovation: Continued investment in R&D for subcutaneous BRIUMVI and azer-cel CAR T therapy, aiming for meaningful new launches in 2027, 2028, and 2029.
Marketing and awareness campaigns: Launched a national television campaign and expanded digital and social media initiatives to drive patient engagement and brand awareness for BRIUMVI.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The discussion includes forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially. These risks are detailed in SEC filings, indicating potential regulatory hurdles.
Strategic Execution Risks: The company is pursuing multiple pivotal studies and product launches, including ENHANCE and subcutaneous ublituximab, which involve complex execution and timelines. Delays or failures in these initiatives could impact strategic objectives.
Market Competition: The anti-CD20 class represents a $10 billion market, but competitive pressures exist as other companies also target this space. TG Therapeutics aims to differentiate with both IV and self-administered options, but competition remains a challenge.
Financial Discipline and Investment Risks: The company has chosen to stay patient with capital deployment, avoiding potentially tempting deals. However, this conservative approach could limit growth opportunities if not balanced effectively.
Supply Chain and Operational Risks: Expansion of the commercial field organization and increased SG&A spending to support BRIUMVI's growth could strain operational efficiency if not managed carefully.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company raised its full-year 2025 U.S. BRIUMVI net revenue guidance from $570-$575 million to approximately $585 million, reflecting favorable demand trends and consistent execution by the commercial team.
Future Product Launches: The company anticipates meaningful new product launches in 2027, 2028, and 2029, which are expected to drive continued growth into the next decade.
ENHANCE Study: The ENHANCE study aims to simplify BRIUMVI dosing by consolidating the day 1 and day 15 doses into a single day 1 infusion. Data is expected by mid-2026, with a potential launch of the new dosing schedule in 2027.
Subcutaneous Ublituximab Study: The Phase III subcutaneous ublituximab study is testing two dosing schedules (every other month and quarterly). Enrollment is expected to complete in the first half of 2026, with top-line data anticipated in late 2026 or early 2027. If successful, approval and launch are targeted for 2028.
Market Expansion: Subcutaneous ublituximab is expected to nearly double the total addressable market for BRIUMVI. If approved, TG Therapeutics would be the only company offering both IV and self-administered CD20 options, providing a competitive advantage.
Azer-cel Development: The company is developing azer-cel, an allogeneic CAR T therapy for progressive MS, which could be life-changing for patients. This is an early-stage development with no specific timeline provided.
Financial Discipline: The company remains operationally profitable and expects this trend to continue, barring any one-time business development moves that could temporarily impact the financial picture but strengthen it in the long term.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: During the quarter, TG Therapeutics completed its initial $100 million share repurchase program, buying back 3.5 million shares at an average price of about $28.50. The Board has now authorized another $100 million program, providing flexibility for further share repurchases.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the headwinds and tailwinds expected for Q4 compared to prior years?
A:The growth assumed in Q4 is 14% quarter-over-quarter, which is considered good. Key factors include better-than-expected patient retention driving demand growth, field expansion, and media investments expected to increase demand.
Q:Are you seeing additional demand from the permanent J-code in place since April?
A:The company clarified that they have had a J-code for several years, so this question may not apply to their product.
Q:What is the focus of field operation expansion for Q4 and next year, and how is the return being measured?
A:The focus is on driving hospital business, which has shown higher demand growth compared to private practice. The addition of new sales reps has expanded reach, leading to consistent growth in new prescribers and accounts.
Q:What factors underpin the estimate that subcutaneous products could double the market opportunity for BRIUMVI in MS?
A:The subcutaneous (subcu) portion of the market is about 35-40% and growing. If subcu reaches 50% of new starts, it could double the market opportunity. This estimate is based on dynamic share rather than total share.
Q:Are there any notable inventory channel dynamics or gross-to-net changes in Q3?
A:There were no inventory changes or gross-to-net changes in Q3. Gross-to-net remains within the provided range.
Q:What are the competitive dynamics versus the current at-home subcutaneous competitor?
A:The subcutaneous segment is growing faster than the IV market and has settled at approximately 65-35 or 60-40 IV to subcu. Future changes are uncertain, but more subcu products could lead to further growth in this segment.
Q:When can we expect initial PK or exposure data from the Phase I BRIUMVI subcutaneous study?
A:The company hopes to present the data in the first half of next year.
Q:Can you explain the ex-U.S. sales of $6.4 million and the accounting of the Neuraxpharm collaboration?
A:Ex-U.S. sales are recorded as product revenue when products are sold to Neuraxpharm, and royalties appear on the license milestone and royalty line.
Q:What are the initial thoughts on 2026 trends, including positives and negatives?
A:Key factors include continued growth in new patients, strong patient retention, and the impact of direct-to-consumer efforts. The company is monitoring these indicators, which are currently encouraging.
Q:Why did the company not pursue certain tempting deals, and what are the criteria for future business development?
A:The company evaluates deals based on ROI, risk-reward, and potential. They passed on deals that did not meet their high standards but continue to look for opportunities that align with their strategic goals.
Q:What are the expectations for fiscal year 2026 guidance, particularly regarding maintenance and growth?
A:Patient persistence is above expectations and is becoming a larger part of the business. The company expects continued new patient growth, market share gains, and positive impacts from direct-to-consumer efforts.
Q:What is the potential read-through from Roche's SLE data to BRIUMVI's program, and does BRIUMVI show potential outside of MS?
A:The company has not reviewed Roche's SLE data yet. However, they believe BRIUMVI has potential in other autoimmune indications like MG, based on encouraging results from a few treated patients.
Q:How is the simplified dosing regimen for BRIUMVI expected to expand market share?
A:The simplified regimen has generated customer excitement, but it is challenging to quantify its impact on market share as it does not address a separate market like subcutaneous products.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance or numerical details for fiscal year 2026, particularly regarding revenue expectations and the impact of the simplified dosing regimen. Additionally, they did not provide a detailed analysis of Roche's SLE data or its implications for BRIUMVI.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACTRIMS Conference
BRIUMVI MG
BRIUMVI azer
BRIUMVI class
BRIUMVI day
BRIUMVI demand
BRIUMVI discipline
BRIUMVI efficacy
BRIUMVI launch
BRIUMVI target
BRIUMVI term
BRIUMVI track
Bosco Therapeutics
CEO flagship
Chief Commercial
Commercial Officer
Communications Bosco
Conference BRIUMVI
Demand physician
ENABLE
base
brand
center community
combination
consistency
efficacy safety
engagement
healthcare provider
outcome
patient center
people
professionalism
record
relapse
schedule
tolerability
treatment patient
trend BRIUMVI
type
ublituximab opportunity
year treatment
TGTX Transcript
TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call highlights a significant revenue increase of 45% YoY, indicating positive financial performance. However, the company's net loss and increased operating expenses raise concerns. Strategic execution and regulatory risks were noted, and management's unclear responses during the Q&A add uncertainty. The lack of discussion on strategic initiatives and shareholder returns further tempers optimism, resulting in a neutral sentiment.
TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reveals strong financial performance with 20% sequential growth and a significant net income increase, even considering the nonrecurring tax benefit. The raised revenue guidance and successful share repurchase program further support a positive outlook. Although operating expenses exceeded guidance, the company's strategic investments are expected to pay off. The Q&A section highlights strong demand and market share gains, with conservative guidance suggesting potential upside. Overall, these factors indicate a positive sentiment and likely stock price increase in the short term.
TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
TGTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
